Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Mar;26(1):1-11.
doi: 10.1055/s-0037-1598183. Epub 2017 Feb 3.

Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension?

Kailash Prasad  1 , Manish Mishra  1
Affiliations
Review

Do Advanced Glycation End Products and Its Receptor Play a Role in Pathophysiology of Hypertension?

Kailash Prasad et al. Int J Angiol. 2017 Mar.

Abstract

There is a close relationship between arterial stiffness and blood pressure. The studies suggest that the advanced glycation end products (AGEs) and its cell receptor (RAGE) are involved in the arterial stiffness in two ways: changes in arterial structure and vascular function. Plasma levels of AGEs and expression of RAGE are elevated, while the levels of soluble RAGE (sRAGE) and endogenous secretory RAGE (esRAGE) are lowered in patients with hypertension (HTN). There is a positive correlation between plasma levels of AGEs and arterial stiffness, and an inverse association between arterial stiffness/HTN, and serum levels of sRAGE and esRAGE. Various measures can reduce the levels of AGEs and expression of RAGE, and elevate sRAGE. Arterial stiffness and blood pressure could be reduced by lowering the serum levels of AGEs, and increasing the levels of sRAGE. Levels of AGEs can be lowered by reducing the consumption of AGE-rich diet, short duration of cooking in moist heat at low temperature, and cessation of cigarette smoking. Drugs such as aminoguanidine, vitamins, angiotensin-converting enzyme (ACE) inhibitors, angiotensin-II receptor blockers, statins, and metformin inhibit AGE formation. Alagebrium, an AGE breakers reduces levels of AGEs. Clinical trials with some drugs tend to reduce stiffness. Systemic administration of sRAGE has beneficial effect in animal studies. In conclusion, AGE-RAGE axis is involved in arterial stiffness and HTN. The studies suggest that inhibition of AGEs formation, reduction of AGE consumption, blockade of AGE-RAGE interaction, suppression of RAGE expression, and exogenous administration of sRAGE may be novel therapeutic strategies for treatment of arterial stiffness and HTN.

Keywords: advanced glycation end products; arterial stiffness; hypertension; management of hypertension; receptor for AGE; soluble receptor for AGE.

PubMed Disclaimer

References

    1. Kearney P M, Whelton M, Reynolds K, Whelton P K, He J. Worldwide prevalence of hypertension: a systematic review. J Hypertens. 2004;22(1):11–19. - PubMed
    1. Wendt T, Tanji N, Guo J. et al. Glucose, glycation, and RAGE: implications for amplification of cellular dysfunction in diabetic nephropathy. J Am Soc Nephrol. 2003;14(5):1383–1395. - PubMed
    1. Schmidt A M, Yan S D, Wautier J L, Stern D. Activation of receptor for advanced glycation end products: a mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res. 1999;84(5):489–497. - PubMed
    1. Schmidt A M, Yan S D, Yan S F, Stern D M. The biology of the receptor for advanced glycation end products and its ligands. Biochim Biophys Acta. 2000;1498(02/03):99–111. - PubMed
    1. Prasad K. New York, NY: The McGraw-Hill Company, INC; 2009. Hypertension; pp. 125–140.